[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20130835T1 - Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru - Google Patents

Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru Download PDF

Info

Publication number
HRP20130835T1
HRP20130835T1 HRP20130835TT HRP20130835T HRP20130835T1 HR P20130835 T1 HRP20130835 T1 HR P20130835T1 HR P20130835T T HRP20130835T T HR P20130835TT HR P20130835 T HRP20130835 T HR P20130835T HR P20130835 T1 HRP20130835 T1 HR P20130835T1
Authority
HR
Croatia
Prior art keywords
inhaler
metered dose
severe
dose inhalers
pharmaceutical solution
Prior art date
Application number
HRP20130835TT
Other languages
English (en)
Inventor
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of HRP20130835T1 publication Critical patent/HRP20130835T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

1. Formulacija otopine koja se daje kao stlačeni inahalat u inhalatoru koja kao aktivne tvari sadrži kombinaciju fromeoterol-fumarata i beklometazon-dipropionata otopljenih u smjesi HFA134a propelanta i 12% v/v etanola kao kootapala te 0.024 % v/v klorovodične kiseline (1M), naznačena time da je za upotrebu u prevenciji i/ili liječenju ozbiljnih bronhopulmonarnih bolesti odabranih od sljedećih: ozbiljna trajna astma ili ozbiljna ili vrlo ozbiljna kornična opstuktivna bolest pluća (COPD), s tim da se pokretanjem rečenog inhalatora isporučuje 50 mL rečene otopine koja sadrži dozu od 6 mg formoterol-fumarata te 100 mg beklametozaom-dipropionata po pokretanju.
2. Otopina prema patentnom zahtjevu 1, naznačena time da je inhalator načinjen od aluminija.
HRP20130835TT 2006-04-21 2007-04-19 Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru HRP20130835T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (1)

Publication Number Publication Date
HRP20130835T1 true HRP20130835T1 (hr) 2013-10-25

Family

ID=38230023

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130835TT HRP20130835T1 (hr) 2006-04-21 2007-04-19 Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru

Country Status (21)

Country Link
US (4) US20060257324A1 (hr)
EP (1) EP2010190B1 (hr)
JP (1) JP5289306B2 (hr)
KR (1) KR101311662B1 (hr)
CN (4) CN102908308A (hr)
AU (1) AU2007241336C1 (hr)
BR (1) BRPI0709510A2 (hr)
CA (1) CA2649556C (hr)
CY (1) CY1114215T1 (hr)
DK (1) DK2010190T3 (hr)
EA (1) EA016262B1 (hr)
ES (1) ES2424753T3 (hr)
HR (1) HRP20130835T1 (hr)
ME (1) ME02342B (hr)
MX (1) MX2008013460A (hr)
PL (1) PL2010190T3 (hr)
PT (1) PT2010190E (hr)
RS (1) RS52940B (hr)
SI (1) SI2010190T1 (hr)
WO (1) WO2007121913A2 (hr)
ZA (1) ZA200808965B (hr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
MXPA06013189A (es) * 2004-05-13 2007-02-14 Chiesi Farma Spa Productos medicinales de formulacion en aerosol que tienen estabilidad quimica mejorada.
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010138158A1 (en) * 2009-05-15 2010-12-02 Map Pharmaceuticals, Inc. Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
AR076806A1 (es) * 2009-05-29 2011-07-06 Pearl Therapeutics Inc Composiciones para el suministro de agentes activos mediante las vias res-piratorias, y metodos y sistemas asociados, cosuspension, inhalador dosifi-cador
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
KR101757951B1 (ko) * 2009-12-23 2017-07-13 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
HRP20140550T1 (hr) 2009-12-23 2014-07-18 Chiesi Farmaceutici S.P.A. Aerosolna formulacija za copd
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
RU2567040C2 (ru) * 2009-12-23 2015-10-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
RS53821B1 (en) * 2010-02-16 2015-06-30 Teva Branded Pharmaceutical Products R & D Inc. INHALATION PHARMACEUTICAL COMPOSITION
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102266560A (zh) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 一种用于治疗气喘的药物组合物
RU2568882C2 (ru) * 2010-07-16 2015-11-20 Сипла Лимитед Фармацевтические композиции
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
SG11201605311UA (en) 2013-12-30 2016-07-28 Chiesi Farma Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
CA3037107C (en) * 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
ES2956521T3 (es) * 2016-09-19 2023-12-22 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de tiotropio
CN109789126B (zh) 2016-09-19 2022-08-05 墨西哥氟石股份公司 药物组合物
AU2017328908B2 (en) 2016-09-19 2020-04-02 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2019282562A1 (en) 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
EP4069189A1 (en) 2019-12-02 2022-10-12 Chiesi Farmaceutici S.p.A. Stainles steel can for pressurised metered dose inhalers
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0616525T3 (da) 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338753C (en) * 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
ES2193726T3 (es) * 1998-08-04 2003-11-01 Jago Res Ag Formulaciones de aerosol medicinales.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
AU2206801A (en) 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EA005179B1 (ru) * 2000-05-22 2004-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические препараты в виде растворов для дозированных ингаляторов под давлением
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
WO2003074024A1 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A Formoterol superfine formulation
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
MXPA06001642A (es) * 2003-08-11 2006-04-28 Glaxo Group Ltd Inhalador farmaceutico de dosis medida y metodos relacionados con el mismo.
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
AU2006214443C1 (en) * 2005-02-15 2011-11-24 Alkermes Pharma Ireland Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
ES2424753T3 (es) 2013-10-08
US20200085729A1 (en) 2020-03-19
WO2007121913A2 (en) 2007-11-01
JP2009534333A (ja) 2009-09-24
ME02342B (me) 2016-06-20
EP2010190B1 (en) 2013-06-12
CA2649556C (en) 2014-04-15
JP5289306B2 (ja) 2013-09-11
CN101389341A (zh) 2009-03-18
SI2010190T1 (sl) 2013-10-30
CN102908308A (zh) 2013-02-06
CA2649556A1 (en) 2007-11-01
RS52940B (en) 2014-02-28
BRPI0709510A2 (pt) 2011-07-19
ZA200808965B (en) 2009-12-30
CN105963249A (zh) 2016-09-28
US10525006B2 (en) 2020-01-07
AU2007241336A1 (en) 2007-11-01
KR20080110985A (ko) 2008-12-22
AU2007241336C1 (en) 2023-06-29
DK2010190T3 (da) 2013-08-26
PT2010190E (pt) 2013-08-26
US20060257324A1 (en) 2006-11-16
US11213485B2 (en) 2022-01-04
EA016262B1 (ru) 2012-03-30
EA200802012A1 (ru) 2009-04-28
CY1114215T1 (el) 2016-08-31
PL2010190T3 (pl) 2013-11-29
US20090130026A1 (en) 2009-05-21
EP2010190A2 (en) 2009-01-07
US20170065518A1 (en) 2017-03-09
KR101311662B1 (ko) 2013-09-25
WO2007121913A3 (en) 2008-03-06
CN106074359A (zh) 2016-11-09
MX2008013460A (es) 2008-10-29
AU2007241336B2 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
RU2019100425A (ru) Новая доза и препаративная форма
ES2745064T3 (es) Formulación superfina de formoterol
AR101593A2 (es) Formulación superfina de formoterol
RU2006132036A (ru) Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей
JP2016040316A5 (hr)
RU2013142268A (ru) Фармацевтическая композиция
RU2010108640A (ru) Новая комбинация терапевтических агентов
NZ600790A (en) Combination therapy for copd
JP5800829B2 (ja) Ｃｏｐｄ用エアロゾル製剤
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
JP2007520506A5 (hr)
RU2008124825A (ru) Органические соединения, включающие соль гликопиррония
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
AR040450A1 (es) Formulacion superfina de salmeterol
JP2004529108A5 (hr)
EP2563364A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
US20130104881A1 (en) Stabilized Metered Dose Inhaler
JP2005514440A (ja) アミドおよび／またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
JP2011500731A5 (hr)
JP2009506029A5 (hr)
CN118574609A (zh) 可吸入制剂